Fujiwara Keiichi, Kiura Katsuyuki, Gemba Kenichi, Ogata Yoshiko, Hotta Katsuyuki, Kishino Daizo, Tabata Masahiro, Ueoka Hiroshi, Tanimoto Mitsune
Department of Respiratory Medicine, Okayama University Hospital, 2-5-1 Shikata-cho, Okayama 700-8558, Japan.
Anticancer Res. 2005 Jan-Feb;25(1B):547-9.
Gefitinib ('Iressa, ZD1839) has promising antitumor activity in non-small cell lung cancer (NSCLC). However, patients with advanced NSCLC have few treatment options available if they are refractory to gefitinib. We describe four cases of patients with advanced NSCLC who previously responded to gefitinib and obtained significant tumor regression through retreatment with other cytotoxic agents. Gefitinib might restore chemosensitivity to previously chemorefractory patients.
吉非替尼（“易瑞沙，ZD1839”）在非小细胞肺癌（NSCLC）中具有可观的抗肿瘤活性。然而，晚期非小细胞肺癌患者若对吉非替尼耐药，可供选择的治疗方案寥寥无几。我们描述了4例晚期非小细胞肺癌患者的病例，这些患者先前对吉非替尼有反应，并通过再次使用其他细胞毒性药物治疗获得了显著的肿瘤消退。吉非替尼可能会恢复先前对化疗耐药患者的化疗敏感性。
